RecruitingNCT03146910
Swiss Primary Biliary Cholangitis Cohort Study
Sponsor
Fondazione Epatocentro Ticino
Enrollment
500 participants
Start Date
Feb 15, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
Research project in which biological material is sampled and health-related medical data is collected. In addition, already existing health-related medical data are used for further research. Coded data are used.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- diagnose of Primary biliary cholangitis (according to EASL Clinical Practice Guidelines: management of cholestatic liver diseases).
- Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specific anti-nuclear antibodies are also included
- Patients/subjects aged at least 18 years and living in Switzerland are included
Exclusion Criteria1
- N/A
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03146910
Related Trials
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136130 locations
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT0644716865 locations
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617191 locations
Biochemical Response and Clinical Outcomes in Patients With PBC
NCT074497931 location
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
NCT0642739528 locations